Samik Pharmaceutical Company LTD. (KOSDAQ:014950)
South Korea · Delayed Price · Currency is KRW 7,910.00
-390.00 (-4.70%)
At close: Sep 11, 2026
KOSDAQ:014950 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 7,454 | 5,220 | 4,551 | 2,074 |
Short-Term Investments | 20,327 | 20,327 | 4,327 | 2,000 |
Trading Asset Securities | 4,569 | 6,524 | 4,057 | 4,692 |
Cash & Short-Term Investments | 32,349 | 32,070 | 12,935 | 8,766 |
Cash Growth | 76.76% | 147.94% | 47.55% | - |
Accounts Receivable | 8,850 | 9,034 | 8,767 | 9,202 |
Other Receivables | 227.46 | 98.14 | 146.74 | 69.57 |
Receivables | 9,168 | 9,231 | 8,914 | 9,572 |
Inventory | 15,323 | 15,102 | 11,982 | 9,976 |
Prepaid Expenses | 32.61 | 5.21 | 2.13 | 2.44 |
Other Current Assets | 398.47 | 564.87 | 295.98 | 340.98 |
Total Current Assets | 57,272 | 56,974 | 34,129 | 28,658 |
Property, Plant & Equipment | 28,409 | 27,340 | 24,963 | 25,389 |
Long-Term Investments | 34 | 34 | 4,411 | 4,214 |
Other Intangible Assets | 348.18 | 324.52 | 320.91 | 338.49 |
Long-Term Accounts Receivable | - | - | 0 | 0 |
Long-Term Deferred Tax Assets | 576.91 | 206.41 | 97.23 | 94.89 |
Other Long-Term Assets | 62.31 | 289.08 | 387.51 | 337.51 |
Total Assets | 86,744 | 85,223 | 64,309 | 59,032 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 1,981 | 2,468 | 1,742 | 1,490 |
Accrued Expenses | 4,014 | 4,078 | 3,586 | 3,156 |
Current Portion of Leases | 100.87 | 111.66 | 68.91 | 139.37 |
Current Income Taxes Payable | 273.43 | 789.78 | 359.93 | 19.33 |
Other Current Liabilities | 5,488 | 4,299 | 4,675 | 4,071 |
Total Current Liabilities | 11,857 | 11,747 | 10,432 | 8,876 |
Long-Term Debt | - | 2,684 | - | - |
Long-Term Leases | 190.64 | 222.96 | 23.81 | 57.15 |
Pension & Post-Retirement Benefits | 222.48 | 63.12 | 37.12 | 18.47 |
Long-Term Deferred Tax Liabilities | 1,596 | 1,431 | 1,778 | 1,642 |
Other Long-Term Liabilities | 88.52 | 90.42 | 86.21 | 103.1 |
Total Liabilities | 13,954 | 16,238 | 12,357 | 10,697 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 1,007 | 919.64 | 714.95 | 702.5 |
Additional Paid-In Capital | 21,568 | 18,392 | 781.96 | - |
Retained Earnings | 50,919 | 50,125 | 51,166 | 47,925 |
Treasury Stock | - | -15.74 | - | - |
Comprehensive Income & Other | -704.16 | -436.49 | -711.02 | -292.17 |
Shareholders' Equity | 72,790 | 68,985 | 51,952 | 48,335 |
Total Liabilities & Equity | 86,744 | 85,223 | 64,309 | 59,032 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 291.51 | 3,019 | 92.71 | 196.52 |
Net Cash (Debt) | 32,058 | 29,051 | 12,842 | 8,570 |
Net Cash Growth | 76.21% | 126.22% | 49.85% | - |
Net Cash Per Share | 3639.88 | 3829.06 | 1826.67 | 1220.83 |
Filing Date Shares Outstanding | 9.68 | 9.19 | 7.03 | 7.02 |
Total Common Shares Outstanding | 9.68 | 9.19 | 7.03 | 7.02 |
Working Capital | 45,415 | 45,227 | 23,697 | 19,782 |
Book Value Per Share | 7517.39 | 7502.74 | 7389.69 | 6885.80 |
Tangible Book Value | 72,442 | 68,660 | 51,631 | 47,997 |
Tangible Book Value Per Share | 7481.43 | 7467.44 | 7344.04 | 6837.58 |
Land | 19,537 | 19,537 | 18,821 | 18,821 |
Buildings | 8,070 | 8,065 | 7,890 | 7,884 |
Machinery | 11,542 | 11,570 | 11,256 | 10,555 |
Construction In Progress | 3,278 | 1,654 | 177.5 | 288.3 |